L'Oréal to help develop 3D printed skin tissue

Published: 6-May-2015

L'Oréal USA is researching a new product evaluation tool

L’Oréal USA has announced a partnership with 3D bioprinting company Organovo Holdings Inc. The collaboration aims to develop 3D printed skin tissue for product evaluation and other areas of advanced research.

The project will marry L’Oréal’s expertise in skin engineering with Organovo’s proprietary NovoGen Bioprinting Platform. Guive Balooch, Global Vice President of L’Oréal’s Technology Incubator, explained: “Organovo has broken new ground with 3D bioprinting, an area that complements L’Oréal’s pioneering work in the research and application of reconstructed skin for the past 30 years. Our partnership will not only bring about new advanced in vitro methods for evaluating product safety and performance, but the potential for where this new field of technology and research can take us is boundless.”

Organovo’s 3D printers are able to create reproducible, automated human tissues that mimic the form and function of native tissues in the human body. The new partnership is the first-ever application of Organovo’s groundbreaking technology within the beauty industry.

Keith Murphy, Chairman and Chief Executive Officer at Organovo, said: “We are excited to be partnering with L’Oréal, whose leadership in the beauty industry is rooted in scientific innovation and a deep commitment to research and development.” He added: “This partnership is a great next step to expand the applications of Organovo’s 3D bioprinting technology and to create value for both L’Oréal and Organovo by building new breakthroughs in skin modeling.”

You may also like